Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
The FOOD AND DRUG ADMINISTRATION has issued a Tender notice for the procurement of a Novel Approaches To Support Therapeutic Development In Ultra-Rare Cancers in the USA. This Tender notice was published on 05 May 2026 and is scheduled to close on 15 Jun 2026, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 140655571, while the tender notice number is RFA-FD-26-004 and Registering on the platform.
Procurement Summary
Country: USA
Summary: Novel Approaches To Support Therapeutic Development In Ultra-Rare Cancers
Deadline: 15 Jun 2026
Posting Date: 05 May 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 140655571
Document Ref. No.: RFA-FD-26-004
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details Tender Details Background The Fda Oncology Center Of Excellence () Aims To Advance The Development And Regulation Of Oncology Products For Patients With Cancer. The And Were Established To Facilitate And Expedite Drug Development For Pediatric And Other Rare Cancers. Oce-S Connects Scientific Knowledge, Creative Insight, And Medical Professionals To Foster Early-Stage Product Innovation, Which Is Particularly Important To Address The Challenges Related To Product Development For Ultra-Rare Cancers. In Collaboration With The National Institutes Of Health (Nih) And The Oce, The Foundation For The National Institutes Of Health (Fnih) Recently Launched The Design Phase Of The, A New Public-Private Partnership Dedicated To Accelerating The Development Of Innovative Ultra-Rare Cancer Treatments. ... For The Purposes Of This Nofo, The Fda Oce Refers To Cancers With An Approximate Annual Incidence In The U.S. Of 300 To 400 People Or Less As Ultra-Rare (A More Stringent Criterion Compared To The Threshold For A Rare Disease Specified In The Orphan Drug Act Based On A U.S. Prevalence Of ≪200, 000 People). Many Of The Challenges Involved In Drug Development For Ultra-Rare Cancers Are Similar To Those For Rare Diseases And Can Include: Difficulty Enrolling Sufficient Numbers Of Patients To Clinical Trials Limited Financial Incentives For Drug Development Insufficient Understanding Of The Cancer Pathophysiology, Molecular Characteristics, And Natural History Limited Or Lack Of Timely Acc... Documents
Award max: $500, 000
Posted Date: 2026-05-04 00:00:00
Funding instrument type: Cooperative agreement
Procurement Documents for USA
Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google